Investor Relations
Abcam IR Home
Share price & chart
Reports & accounts / Financial Calendar
Regulatory news (RNS)
Contacts & advisors
Governance
CSR statement
Directors
Major shareholders
Other Documents
The Abcam story
About research antibodies
Abcam company news
Main Abcam website

REG-ABCAM Plc Director/PDMR Shareholding

http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20091104:RnsD9236B
RNS Number : 9236B  
  
ABCAM Plc  
  
04 November 2009  
  
 
  For immediate release   4November 2009  
  
  
 ("Abcam" or "the Company")  
  
Director and PDMR Dealings  
  
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that 
markets antibodies via its own online catalogue, announces the following 
transactions undertaken by employees of the Company:  
  
On 3 November 2009, Jim Warwick, as Executive Director of the Company, exercised 
share options over 4,218 ordinary shares of 1 pence each in the Company at an 
exercise price of 224p per share. Following this transaction, Mr Warwick's total 
beneficial interest in the Company is 857,738 ordinary shares representing 
approximately 2.4 per cent. of the current issued share capital of the Company. 
  
  
Also on 3 November 2009, Jane Cooke, a PDMR of the Company, exercised share 
options over 3,375 ordinary shares of 1 pence each in the Company at an exercise 
price of 224p per share. Following this transaction, Mrs Cooke's total 
beneficial interest in the Company is 3,724 ordinary shares representing 
approximately 0.01 per cent. of the current issued share capital of the Company. 
  
  
For further information please contact:  
  
 
  Abcam                                               + 44 (0) 1223 696000   
  Jonathan Milner, Chief Executive Officer                                   
  Jeffrey Iliffe, Chief Financial Officer                                    
                                                                             
  Numis Securities                                    + 44 (0) 20 7260 1000  
  Michael Meade / Nick Westlake - Nominated Adviser                          
  James Black - Corporate Broking                                            
                                                                             
  Buchanan Communications                             + 44 (0) 20 7466 5000  
  Mark Court / Mary-Jane Johnson / Stasa Filiplic                            
  
  
Notes for editors:  
  
About Abcam plc  
  
Abcam is a producer and distributor of research-grade antibodies headquartered 
in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA, 
Tokyo, Japan and Hong Kong. Abcam was admitted to AIM in November 2005 and 
trades under the ticker symbol ABC. The Company produces and distributes its own 
and third-party produced antibodies to academic and commercial users throughout 
the world. Product ordering is available through the Company's website 
www.abcam.com, where customers are also able to access up-to-date and detailed 
technical product data sheets. All the antibodies are sold under the Abcam brand 
name and the Company's vision is to build the world's largest online resource of 
high-quality and commercially viable antibodies. Abcam now has an online 
catalogue of over 56,000 products, most of which are antibodies, from over 250 
suppliers and employs 243 staff in its four operating companies.  
  
 
This information is provided by RNS  
  
The company news service from the London Stock Exchange  
  
  END  
  
RDSKZLBBKFBEFBE  
  

---

back to RNS news